News & Press

Follow our news to learn how Dermagnostix is redefining molecular diagnostics in dermatology with our point-of-need microfluidics platform.


Subscribe to our newsletter!

News

Dermagnostix expands US business development by Eureka Innowwide funding and acceptance into German Accelerator

By participating in several conferences and trade shows in the US – most recently at the ISDP meeting in San Diego – Dermagnostix has already been able to show that the interest in PsorX is high and the feedback is consistently positive. In 2024, the focus will shift even more to business development in the USA. The

March 18, 2024
read more
Dermagnostix expands US business development by Eureka Innowwide funding and acceptance into German Accelerator

DX featured at Kompass Dermatologie

Dermagnostix is featured in the journal series ‘Karger Kompass’ aimed at clinicians and specialists in private practice with a focus on young, committed physicians with four specialist target groups of pneumologists, dermatologists, oncologists and ophthalmologists.

March 10, 2023
read more
DX featured at Kompass Dermatologie

Press information

Dermagnostix is a young medtech company redefining molecular diagnostics in dermatology based on a cutting-edge point-of-need microfluidics platform. Our goal is to help patients around the globe get accurate, timely diagnoses.

Dermagnostix announces PsorX-LabDisk as their first CE-IVD

Dermagnostix announces PsorX LabDisks are now CE-IVD test kits in Germany. PsorX is a first in-class molecular test to support differential diagnosis of psoriasis and eczema or atopic dermatitis. PsorX two-gene classifier accurately and efficiently distinguishes psoriasis from eczema, even in cases where conventional diagnostic methods have failed.

read more
Dermagnostix announces PsorX-LabDisk as their first CE-IVD

Dermagnostix achieves EN ISO 13485:2016 certification

Dermagnostix proudly announces completion of ISO certification. Dermagnostix passed Stage 1 of ISO certification in May, 2022 and was recommended for Stage 2. In December we fully qualified our products for market entry and passed stage 2 to complete the certification of Dermagnostix and implementation of PsorX in a fully automated miniature laboratory for minimally

read more
Dermagnostix achieves EN ISO 13485:2016 certification

Dermagnostix announces commercial pilot of PsorX-LabDisk

Dermagnostix announces the commercial pilot of PsorX LabDisks as CE-IVD test kits in Germany. PsorX is a first in-class molecular test for differential diagnosis of psoriasis and eczema or atopic dermatitis. PsorX two-gene classifier accurately and efficiently distinguishes psoriasis from all forms of eczema, even in cases where conventional diagnostic methods have failed.

read more
Dermagnostix announces commercial pilot of PsorX-LabDisk

PsorX- LabDisk announces CE-IVD mark for PsorX-LabDisk and LabDisk-Analyzer

Dermagnostix announces CE-IVD mark for PsorX LabDisk and LabDisk-Analyzer. CE-IVD mark for PsorX provides our customers with the knowledge and assurance that our point of need solution is developed with the highest standards for efficacy and safety. “The receipt of the CE-IVD mark is an important milestone for Dermagnostix as we move towards commercialization. It

read more
PsorX- LabDisk announces CE-IVD mark for PsorX-LabDisk and LabDisk-Analyzer